Every Form 4 that Precigen Inc (PGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PGEN filings page.
A director of Precigen, Inc. reported selling 235,467 shares of common stock on 12/12/2025. The shares were sold at a weighted average price of $3.6349, with individual trades executed at prices ranging from $3.5000 to $3.7100.
Following these sales, the director beneficially owns 110,603 shares of Precigen common stock in direct ownership. The filing notes that full details of the number of shares sold at each price within the stated range are available upon request.
Precigen, Inc. (PGEN) reported insider activity by director and 10% owner Randal J. Kirk on a Form 4. Through entity Kapital Joe, he sold 1,086,153 shares of common stock on 11/19/2025 at a weighted average price of $4.47, 942,832 shares on 11/20/2025 at a weighted average price of $4.08, and 937,308 shares on 11/21/2025 at $3.83.
The filing notes that the first two prices are weighted averages for multiple trades within reported price ranges, and Kirk undertakes to provide full trade details on request. After these sales, he continues to report large indirect beneficial ownership positions in Precigen through multiple entities, including 7,434,384 shares held by Kapital Joe and 82,164,767 shares held by R.J. Kirk Declaration of Trust, along with additional holdings through various family and investment vehicles.
PRECIGEN, Inc. (PGEN) Form 4: Director Jeffrey B. Kindler reported two separate sales of company common stock. On 09/29/2025 he sold 67,523 shares at a weighted-average price of $3.60, and on 09/30/2025 he sold 106,837 shares at a weighted-average price of $3.38. Following the 09/29/2025 sale his beneficial ownership in the reported class was 452,907 shares (direct). Following the 09/30/2025 sale his beneficial ownership was 346,070 shares (direct). The form includes explanatory footnotes that the reported prices are weighted averages across multiple transactions and that the filer will provide details on request. The Form 4 is signed by Jeffrey B. Kindler by attorney-in-fact Donald P. Lehr.
Rutul R. Shah, Chief Operating Officer and director of Precigen, Inc. (PGEN), reported a purchase of 2,000 shares of Precigen common stock on 09/26/2025 at a reported price of $3.40 per share. After this transaction the reporting person beneficially owned 405,959 shares. The Form 4 was signed on behalf of Mr. Shah by an attorney-in-fact on 09/30/2025. The filing indicates the form was submitted by one reporting person and does not disclose any derivative transactions or additional changes to ownership beyond the common stock purchase.
Phil Tennant, Chief Commercial Officer of Precigen, Inc. (PGEN), reported an insider purchase. On 09/29/2025 he acquired 6,000 shares of Precigen common stock at $3.58 per share. Following the transaction he beneficially owned 65,031 shares. The Form 4 was signed on 09/30/2025 by an attorney-in-fact.
Insider purchases by Precigen CFO increased his stake in the company. Harry Thomasian Jr. acquired 8,284 shares on 09/25/2025 at a weighted average price of $3.62 and 2,932 shares on 09/26/2025 at $3.42, bringing his total beneficial ownership to 468,626 shares. The filing shows the transactions were reported on Form 4 and the price for the 09/25 purchases is a weighted average of trades between $3.53 and $3.67. The report was signed on 09/26/2025 by an attorney-in-fact on behalf of the reporting person.
Randal J. Kirk, a director and 10% owner of Precigen, Inc. (PGEN), reported multiple transactions in mid-September 2025. On 09/17/2025 the reporting person received 25,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock sold in a private placement, convertible into 17,385,257 common shares at a conversion mechanism described in the agreement. On 09/18/2025 and 09/19/2025 the reporting person (through entities he controls) sold a total of 5,000,252 common shares: 1,403,360 shares at a weighted average price of $3.86 and 3,596,892 shares at a weighted average price of $3.68. The filing lists multiple entities controlled by Mr. Kirk that hold beneficial ownership interests and disclaims direct beneficial ownership except for pecuniary interest.
Helen Sabzevari, President and CEO and a director of Precigen, Inc. (PGEN), reported the vesting of performance stock units. On 09/12/2025, the second installment of PSUs granted August 28, 2024 vested, resulting in 825,000 shares of common stock being issued or payable in cash equivalent value. The filing lists the shares as directly owned following the transaction. The Form 4 was signed on behalf of Ms. Sabzevari by an attorney-in-fact and filed on 09/16/2025. The document states each PSU converts to one share or an equivalent cash amount.
Harry Thomasian Jr., Chief Financial Officer of Precigen, Inc. (PGEN), reported the vesting of 125,000 performance stock units (PSUs) on 09/12/2025. These PSUs were part of a grant made on August 28, 2024; the filing states the second installment vested after meeting the applicable performance condition. Each PSU may be settled in one share of the company’s common stock or an equivalent cash amount. Following the reported transaction, Mr. Thomasian directly beneficially owns 125,000 shares attributable to these vested PSUs. The Form 4 was signed on 09/16/2025.
Donald P. Lehr, Chief Legal Officer of Precigen, Inc. (PGEN), reported the vesting of 54,000 performance stock units (PSUs) on 09/12/2025. The filing shows those PSUs converted into 54,000 shares of the issuer's common stock (or an equivalent cash amount) at a reported price of $0, resulting in direct beneficial ownership of 54,000 shares following the transaction. The PSUs represent the second installment of an award originally granted on August 28, 2024 and vested based on achievement of the applicable performance condition for that installment. The form is signed by Mr. Lehr on 09/16/2025.
Phil Tennant, Precigen Chief Commercial Officer, reported the vesting of 25,000 performance stock units (PSUs) on 09/12/2025 that converted to common stock. The Form 4 shows these PSUs were part of an award originally granted August 28, 2024 and represent the second installment that vested after achievement of the applicable performance condition. Each PSU is payable in one share of the issuer's common stock or a cash equivalent. Following the reported transaction, Mr. Tennant beneficially owns 25,000 shares of Precigen common stock. The Form 4 was signed by attorney-in-fact Donald P. Lehr on 09/16/2025.
Rutul R. Shah, Chief Operating Officer of Precigen, Inc. (PGEN), reported the vesting of 125,000 performance stock units on 09/12/2025. The filing shows these units are the second installment of PSUs originally granted on August 28, 2024 and vested upon achievement of the applicable performance condition for that installment. Each PSU is payable in one share of common stock or a cash equivalent. Following the reported transaction the filing lists 125,000 shares beneficially owned as a direct holding. The Form 4 is signed on behalf of Mr. Shah by an attorney-in-fact on 09/16/2025.